



Apomorphine in the treatment of Parkinson’s 
disease: a review
O uso da apomorfina no tratamento da doença de Parkinson: revisão da literatura
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The management of Parkinson’s disease (PD) aims for 
adequate control of motor and nonmotor symptoms, mini-
mizing the adverse effects of medications1. A wide range of 
therapeutic options are available and can be used to tailor 
treatment to the needs of individual patients. These include 
dopamine replacement therapy using levodopa; direct stim-
ulation of striatal dopamine receptors by dopamine agonists; 
and other interventions in dopamine metabolism using 
monoamine oxidase-B, DOPA decarboxylase or catechol-
O-methyltransferase inhibitors2. Despite being used since 
1960, and enduring as the most powerful antiparkinsonian 
drug, levodopa is associated with a high incidence of motor 
complications3, with 24% to 89% of patients developing dys-
kinesias after long-term continuous exposure to this drug4. 
There is debatable data on the role of  dopamine agonists 
in postponing or minimizing these complications when 
used as monotherapy or in combination with lower doses of 
levodopa4. In addition, PD presents almost invariably with 
nonmotor symptoms that include mood and cognitive dis-
orders (anxiety, depression, dementia and psychosis), auto-
nomic dysfunction (urinary incontinence, constipation, 
dysphagia, gastroparesis, erectile dysfunction, orthostatic 
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ABSTRACT
Optimizing idiopathic Parkinson’s disease treatment is a challenging, multifaceted and continuous process with direct impact on patients’ 
quality of life. The basic tenet of this task entails tailored therapy, allowing for optimal motor function with the fewest adverse effects. 
Apomorphine, a dopamine agonist used as rescue therapy for patients with motor fluctuations, with potential positive effects on nonmotor 
symptoms, is the only antiparkinsonian agent whose capacity to control motor symptoms is comparable to that of levodopa. Subcutaneous 
administration, either as an intermittent injection or as continuous infusion, appears to be the most effective and tolerable route. This 
review summarizes the historical background, structure, mechanism of action, indications, contraindications and side effects, compares 
apomorphine infusion therapy with other treatments, such as oral therapy, deep brain stimulation and continuous enteral infusion of 
levodopa/carbidopa gel, and gives practical instructions on how to initiate treatment.
Keywords: Apomorphine; dopaminer agents; Parkinsons disease; review.
RESUMO
A optimização do tratamento da doença de Parkinson idiopática se faz um desafio, pois tem impacto direto na qualidade de vida do 
paciente. O melhor esquema terapêutico é o que permite o melhor controle motor com os menores efeitos adversos, através de terapêutica 
individualizada. A apomorfina é o único medicamento antiparkinsoniano que pode ser comparável à potência da levodopa no controle 
dos sintomas motores. Trata-se de um agonista dopaminérgico empregado na terapia de resgate em pacientes com flutuações motoras e 
também contribui para a melhora de muitos sintomas não motores. A via subcutânea, com injeções intermitentes, ou com infusão contínua, 
parece ser a melhor opção pela eficácia e tolerabilidade. Essa revisão resume aspectos históricos, estrutura da molécula, mecanismo de 
ação, indicação, contra-indicação e efeitos colaterais, compara a terapia de infusão com apomorfina com outros tratamentos, como a 
terapia oral, estimulação cerebral profunda e infusão enteral contínua de levodopa/carbidopa gel, e fornece instruções práticas de como 
iniciar o tratamento.
Palavras-chave: Apomorfina; dopaminérgicos; doença de Parkinson; revisão. 
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hypotension, excessive sweating, drooling), pain, and sleep 
disturbances, that have a significant impact on quality of 
life, comparable or occasionally more severe than the motor 
aspects of the disease5. 
Given the complexity of PD and its multiple layers of rele-
vant clinical implications, it is quite common that, even with 
optimal therapy, some patients remain inadequately con-
trolled, requiring invasive treatment2,6, i.e., deep brain stimu-
lation (DBS), enterally-delivered levodopa/carbidopa gel and 
subcutaneous apomorphine3,5.
The objective of this review is to describe the current role 
of apomorphine in the treatment of PD.  
METHODS
We performed a review of the literature based on review 
articles, expert opinion manuscripts and clinical trial 
reports from the PubMed database, using the following 
descriptors: apomorphine, Parkinson’s disease, motor fluc-
tuations, deep brain stimulation and intestinal levodopa/
carbidopa. The search was limited to articles published 
between 1984 and 2017. 
Historical review
Apomorphine was the first dopamine agonist with pow-
erful antiparkinsonian effects used in clinical practice2 and 
predated levodopa by ten years7-12. Derived from morphine, 
it was initially used as an emetic, expectorant, sedative, 
antipsychotic and anticonvulsant, as well as for managing 
drug and alcohol addiction (Figure 1)8,13. Apomorphine is a 
highly-lipophilic, short-acting, nonergot dopamine agonist 
that acts on D1 and D2 dopamine receptors8,9,13,14. It was 
synthesized for the first time in 1869 by Matthiessen and 
Wright9 and, although Weill recommended its use for PD 
in 1884, the first trials started in 1950, according Wenzel,9 
Cotzias,15 and Lees16. In 1951, Schwab et al.17 observed 
improvements in rigidity and tremor in PD patients 
5-10 minutes after subcutaneous administration of a 0.5 to 
1.0 mg dose of apomorphine. These findings were later cor-
roborated by Cotzias et al.13,15,16. 
Oral administration of apomorphine required large 
doses to achieve the desired clinical response, and an exac-
erbated peripheral response was therefore common. This 
could include nausea, vomiting, postural hypotension and 
impaired kidney function, reflected in elevated urea and 
creatinine16. Various administration routes were explored 
to avoid these adverse effects, the most successful of which 
proved to be the subcutaneous7,8,9,18,20,21,22. 
Apomorphine is superior to other dopamine agonists 
such as lisuride because it has fewer adverse effects and 
induces significant improvement in motor and nonmotor 
symptoms, including hyperhidrosis, nocturia, urge inconti-
nence, fatigue and mood disturbances, in addition to been 
well tolerated in patients with visual hallucinations, illusions 
and paranoid ideation23,24. It also improves sleep disorders, 
such as insomnia and restless legs syndrome, without wors-
ening daytime drowsiness24.
In 1988, a group led by Lees, developed a mechanism 
for continuous subcutaneous apomorphine infusion, which 
was later routinely recommended for patients with severe, 
refractory “off ” periods10. Although continuous apomor-
phine treatment was first introduced by Stibe et al.10 in 
1988, subcutaneous injections were only approved by the 
FDA for use in motor “off ” periods in 200414. The long-term 
effectiveness of apomorphine as a rescue medication was 
also investigated in study APO302, in which 62 patients who 
had been having rescue injections for at least three months 
were assessed25. In a comparative assessment on the UPDRS 
scales, there was a significant reduction in motor score after 
10 and 20 minutes25.
Mechanism of action of apomorphine
Apomorphine binds to pre- and postsynaptic recep-
tors and exerts a therapeutic effect by direct stimulation 
of postsynaptic striatal dopamine D2 receptors, result-
ing in activation of the direct pathway and inactivation of 
the indirect striatopallidal pathways1,7,8,11,15,26,27. The motor 
response occurs after a single dose of subcutaneous apo-
morphine and is similar to that of levodopa but with faster 
onset (approximately 4-12 minutes), with a mean effect dura-
tion of 45–60 minutes1,16. In light of these therapeutic effects, 
it became one of the prototypic “rescue medications” in cases 
of unpredictable “off ” periods, as in the case of patients with 
advanced PD and poorly-controlled motor fluctuations, 
who experience erratic gastric emptying7,8,9,10,12,22,25,28,29,30,31,32. 
Furthermore, it does not share transport mechanisms or 
metabolic pathways with levodopa and, unlike levodopa, 
does not require an active transport mechanism to reach 
the central nervous system7,8,9,10,18,28,31. Absorption varies with 






(Extracted from Google Images: Pharmajet, August 6, 2017)
Figure 1.  Apomorphine: molecular structure.
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achieved when it is injected into the subcutaneous tissue of 
the abdominal wall.  There is no interaction with cytochrome 
P450 inhibitors, and the cytochrome P450 system does not 
interfere with the metabolism of this dopamine agonist. Age, 
gender, disease duration, levodopa dosage or duration of 
apomorphine therapy do not appear to play any role in the 
clearance of the medication.11,23-25
When should apomorphine be used?
The first consideration for the use of apomorphine 
must be the confirmed diagnosis of levodopa-responsive 
PD1,11,33,34. Age is typically not a limiting factor, and mild cog-
nitive impairment and axial symptoms are not contraindica-
tions.35,36,37,38,39 Indications for apomorphine include patients 
with refractory “off ” periods, e.g., when there is a delay in 
the onset of the effects of orally administered medication; 
patients who have major “off ” periods upon waking up; and 
patients with significant wearing-off periods7,8,9,10,11,27,28,32,38,40,41. 
It can also improve nonmotor symptoms such as urinary dis-
turbances3,24,35 and serve as a diagnostic clue when diagnosis 
of PD is uncertain1,18,33.
The therapeutic response to maximum levodopa doses 
does not vary in PD but is less consistent in patients with 
multiple system atrophy. Some patients with other parkinso-
nian syndromes are unresponsive or do not respond well to 
levodopa1,11,33. A study by the group led by Lees showed that 
apomorphine can be used as a diagnostic test of response to 
levodopa and has an accuracy of 90%1. The study concluded 
that a response to apomorphine supports a diagnosis of 
PD, while failure to respond indicates that this diagnosis is 
extremely unlikely1.
Routes of administration for apomorphine
Various routes of administration have been investi-
gated8,11,19-22,27,40. Oral administration was first tried by Cotzias, 
who increased the dose gradually to 1,500 mg a day15. Tolerance 
of 150 to 1,440 mg daily doses was generally good, but higher 
doses caused azotemia7,10,11,39. The bioavailability of apomor-
phine administered by this route is less than 4% and this route 
was therefore considered unfeasible, as it required very high 
doses to achieve the desired effect, leading to significant side 
effects such as nephrotoxicity, reflected in elevated creatinine 
and urea11,18. Bioavailability of sublingual apomorphine is also 
low (10–22%), and a 3 mg subcutaneous dose and 30 mg sub-
lingual dose have similar pharmacological profiles and clinical 
responses11,27. Using this route, Ondo et al.42 reported an effect 
duration of between 60 and 130 minutes, while Hughes et al.29 
reported a latency of up to 25 minutes and effect duration of 
118 minutes. Apomorphine can cause nausea, orthostatic hypo-
tension, an unpleasant taste and severe stomatitis, the latter 
being reported in about 50% of patients7,8,9,10,11,18,39. The intrana-
sal spray has a pharmacokinetic profile similar to that of sub-
cutaneously administered apomorphine but requires pretreat-
ment with domperidone11,20,27,42,43.  Latency to effect has been 
shown to be between 5 and 15 minutes, and the effect duration 
between 30 and 60 minutes11,20,27,43. In a study by Obering et al.27, 
the “off ” period was significantly reduced from 5.3 hours/day to 
3.8 hours/day. In another study on the use of apomorphine in 
PD, no statistically significant difference was observed between 
levodopa and apomorphine in terms of the UPDRS score18.
Intermittent apomorphine injection
Ideally, the first dose should be administered in a hospital 
setting so that the clinical response can be observed and a 
tailored therapeutic dose identified1,6,11. 
Peripheral dopaminergic adverse events can occur as a com-
plication of injections of apomorphine, particularly nausea. Oral 
domperidone (10–20 mg three times a day, should be started 
one to three days before apomorphine therapy1,11 (Box 1).
Currently, penject (intermittent injection) and portable 
minipumps (continuous infusion) have been approved in 
most European countries (Figures 2 and 3), where they play 
an important role in advanced PD treatment and have yielded 
good results11,14,15,30,31,35. Hughes et al.1 published a study of 71 
patients treated with intermittent injections (10/day) or con-
tinuous infusion (when more than 10 injections were needed). 
In 49 patients treated with intermittent injections, there was a 
50% reduction in “off ” time. After one year of treatment, 80% of 
the patients reported that the therapy was still effective1. 
Intermittent infusion of apomorphine (penject) is per-
formed with an insulin syringe mounted in an injector 
pen with premarked doses for ease of administration11,15,23. 
Injections sites can be administered in the abdominal 
region, arms and thighs11,12. The number of injections can 
vary between 1 and 30, and the dose can vary between 1 mg 
1) Pretreatment with domperidone. (10–20 mg three times/
day, started one to three days before apomorphine therapy)
2) Performed when the patient has been off dopamine med-
ication for 12-24 hours. Levodopa should be suspended the 
night before the test.
3) Measure blood pressure with the patient lying down, and 
seated, before the test.
4) Start with 1 mg to 1.5 mg subcutaneous apomorphine. 
Record the UPDRS-III score (pre- and post-apomorphine 
– ON, OFF) and any adverse effects (nausea, orthostatic 
hypotension, drowsiness, and dyskinesias).
5) Repeat administration of apomorphine at intervals of 1 
to 1.5 hours, increasing the dose by 1 mg until a good or 
acceptable clinical effect is observed.
No more than 7–8 mg per hour of apomorphine should be 
administered. 
Box 1. Apomorphine test.
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and 10 mg per injection11,23. Apomorphine solution is sup-
plied at a concentration of 1 mg/0.1 mL in 3 mL (30 mg) 
glass cartridges with a manual reusable multidose injector 
pen that releases doses from 0.02 mL to 1 mL (10 mg)11,15,23. 
To minimize mistakes, the apomorphine dose should be pre-
scribed in milliliters (rather than milligrams) as the injector 
pen uses this unit. An optimal therapeutic dose is between 
0.3 mL and 0.5 mL, or 3 mg and 5 mg11,23. Once a suitable 
dose has been identified, it rarely needs to be adjusted. The 
half-life of apomorphine is 45 minutes, and the minimum 
recommended time between injections is 60 minutes11,23. 
The drug is absorbed quickly after subcutaneous injection, 
reaching maximum serum levels in 20 minutes, and the 
clinical effect can be observed between 5 and 15 minutes 
after administration11,13,23. Apomorphine is generally indi-
cated for short periods. The mean daily dose is 3–30 mg/
day, and it is important to determine the dose required to 
reverse the “off ” period11,23. Intermittent apomorphine infu-
sion is a good rescue therapy in cases of motor fluctua-
tions, such as wearing-off and on-off fluctuations, because 
of its fast action11,12,23. When required, apomorphine should 
be used as a rescue medication during “off ” periods, with-
out changing the levodopa schedule. It can reverse pre-
dictable and unpredictable “off ” periods and is indicated 
when the “on” period is delayed11,15,23. It helps with morn-
ing or nocturnal akinesia as well as painful dystonias, and 
is a suitable choice when absorption of orally administered 
levodopa is hampered by delayed gastric emptying11,12,23. 
Apomorphine can also improve psychiatric symptoms such 
as depression and panic attacks24. Some surgical centers 
use apomorphine administered by penject as a rescue med-
ication in preoperative patients when oral medication can-
not be administered11,23.
Continuous apomorphine infusion
An infusion pump is recommended when “off ” periods 
are poorly controlled by oral treatment or when apomor-
phine injections are effective but required more frequently 
(more than 4–6 times a day)11,23,44,45. The patient can be kept 
in a continuous “on” state with an improvement in dyski-
nesias, and the levodopa dose can be reduced11,23,36. Like 
intermittent infusion, continuous infusion of apomorphine 
helps nonmotor symptoms such as pain and mood swings. 
This form of administration is recommended for patients 
in whom duodenal levodopa infusion and DBS are contra-
indicated. Of the options available for advanced stages of 
the disease, it is the least invasive36. Unlike with DBS, age 
and neuropsychiatric changes are not absolute contra-
indications for apomorphine infusion11,46,47. Continuous 
apomorphine infusion is also an alternative to oral treat-
ment, which is complex and may have limited adherence 
or may not result in adequate absorption, as it minimizes 
drug interactions when the patient is taking several medi-
cations6,11,23. Various studies have shown that the levodopa 
dose can be reduced by between 16% and 18% after apo-
morphine is started1,11,23. Apomorphine can also reduce the 
“off ” period by 50% to 80% and guarantees patient mobility 
during the day even in the absence of levodopa6,11,23. 
The initial assessment should include an electrocar-
diogram to exclude the presence of a long QT interval, 
(Courtesy Prof. Andrew Lees.)
Figure 3. Apomorphine: pump.
(Extracted from Google Images: Drugs.com, August 6, 2017)
Figure 2. Apomorphine: penject.
1) Hemolytic anemia
2) ECG changes (prolonged QT, atrial fibrillation, tachycar-
dia, bradyarrhythmias, premature ventricular contractions)
3) Use of anticoagulants
4) Diabetes and other diseases that inhibit healing of surgi-
cal wounds
5) Cellulite and other local infections
6) Hypersensitivity to apomorphine or components of the 
formulation, such as sodium metabisulfite.
7) Severe psychiatric symptoms.
Box 2. Contraindications for apomorphine.
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tachycardia, bradyarrhythmias, atrial fibrillation and prema-
ture ventricular contractions, and should exclude pre-exist-
ing hemolytic anemia4,11. Box 2 shows the main contraindica-
tions for use of apomorphine. 
One day before starting apomorphine treatment, patients 
should be pretreated with 10 mg of domperidone, which 
can be discontinued as soon as possible, when the adverse 
effects of apomorphine have been controlled6,11. The teflon 
delivery needle is inserted in the subcutaneous tissue of the 
abdominal wall, and the site is changed at least every day. 
Continuous infusion is usually started in a hospital setting, 
with a flow rate of 0.5 or 1 mg/hour during the first day. The 
infusion cycle is generally 12–24 hours a day (typically 16 
hours), and the usual dose is 4-7 mg/hour11,46. The hourly flow 
rate is adjusted depending on its effectiveness and patient 
tolerability. Generally, the rate is increased by 0.5-1.0 mg/
hour every day during the initial period and more slowly after 
that at weekly intervals. Some patients are encouraged to use 
a booster dose in anticipation of “off ” periods11,46.
In patients being treated with continuous subcutaneous 
infusion of apomorphine, oral dopamine agonists can gradu-
ally be discontinued during the apomorphine titration period12. 
Sudden interruption of these agonists can lead to dopamine 
agonist withdrawal syndrome11,12. Other antiparkinsonian med-
ications (monoamine oxidase-B inhibitors, catechol-O-meth-
yltransferase inhibitors, amantadine, anticholinergics) should 
then be discontinued gradually, usually in the first seven days11,12. 
Levodopa is generally reduced when the desired therapeutic 
dose of apomorphine is reached but can be reduced when apo-
morphine is started if dyskinesia is present11,12,37.
Adverse events
The most common long-term side effect, which occurs in 
up to 70% of individuals, is nodules at the injection site11,14. 
Some patients may develop itching, bruising or pain. These 
local adverse effects are related to drug concentration, infu-
sion time or injection depth11,14. In some patients (10–20%) 
reactions may be more severe, and necrotic nodular ulcer-
ations or panniculitis may occur. This can be solved by rotat-
ing the injection site every day, ensuring asepsis, applying 
silicone gel patches or, in some cases, it may be necessary to 
use ultrasound treatment11,14. García Ruiz et al.40 found that 
sedation occurred in 29% of patients using an apomorphine 
pump. Orthostatic hypotension can be a manifestation of 
dysautonomia or due to dopamine stimulation and can be 
improved with domperidone. In some cases, patients may 
need to wear compression stockings, keep their legs raised 
and take salt tablets or even fludrocortisone together with 
midodrine11,12. Hematological tests at regular intervals are 
recommended to avoid the risk of hemolytic anemia11,12.
Electrocardiographic changes (QT prolongation) can 
occur with doses of 6 mg or more. Prophylactic treatment 
with dopamine antagonists (e.g., metoclopramide and pro-
chlorperazine) and serotonin receptor antagonists (e.g., 
granisetron and ondansetron) should be avoided because 
these agents cross the blood-brain barrier and can interact 
with apomorphine6,11. When used with ondansetron, apo-
morphine can cause severe hypotension and loss of con-
sciousness6,11. Concomitant use of 5-HT3 antagonists is 
contraindicated. Doses of more than 6 mg do not lead to 
additional benefits and are not recommended11,12.
Table 1 summarizes the main adverse effects of subcuta-
neous apomorphine.
Conventional oral treatment vs. apomorphine
The quality of the response to oral levodopa is indis-
tinguishable from the quality of the response to apomor-
phine11,16. Apomorphine, however, produces a shorter motor 
response, supporting the idea that the integrity of the post-
synaptic receptors is the key factor that determines the 
dopamine response in Parkinson’s disease treatment. In 
other words, the clinical responses to the drugs are the same 
although they have different mechanisms of action11,16.
Apomorphine has various advantages over levodopa, 
such as the fact that it is a monotherapy and increases the 
“on” period by maintaining a continuous dopamine stimulus, 
reducing the need for levodopa and, in turn, reducing dyski-
nesias and motor fluctuations6,11,37,44,45.
As it is administered parenterally, apomorphine improves 
treatment adherence in patients who cannot tolerate oral 
medicine or in whom absorption is erratic6,11. However, it 
requires help from relatives or caregivers to handle the pump. 
Furthermore, apomorphine crosses the blood-brain barrier 
quickly without depending on an active transport system 
and without competing with proteins in the circulation1,11.
Other device-aided therapy strategies vs. 
apomorphine
Deep brain stimulation is currently widely accepted as 
an alternative in stages of PD when motor complications 
Table 1. Adverse effects associated with apomorphine.
Local Subcutaneous nodules, local allergy, panniculitis. 
Systemic Fatigue, nausea, dizziness, orthostatic hypotension and mental confusion, yawning.
Hematological Hemolytic anemia.
Psychiatric Psychosis (associated with the patient’s cognitive decline and disease duration and severity), dopamine dysregulation syndrome and impulse control disorder.
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are significant, or the symptoms of the disease are not well 
controlled37,38,47. Deep brain stimulation of the subthalamic 
nucleus and apomorphine infusion produces significant 
improvements in parkinsonian symptoms and motor fluc-
tuations through different mechanisms2,11,38,39,47. The choice 
of therapy depends on the profiles of individual patients. 
Although the surgical procedure is considered relatively 
safe, it obviously is not risk-free and potential adverse 
effects of DBS include hypophonia and other bulbar symp-
toms, behavioral and cognitive changes, infections, tran-
sient confusion, seizures, intracranial bleeding, and vari-
ous forms of hardware dysfunction11,38,47,48. For example, a 
Spanish study that compared DBS and treatment with apo-
morphine showed that neuropsychological testing for the 
apomorphine group did not change, while for the patients 
who underwent DBS surgery, verbal phonemic fluency and 
word-naming speed were affected negatively47. Additionally, 
apomorphine infusion therapies can be used in patients 
with severe cognitive impairment and psychiatric disorders. 
Borgemeester et al. published a retrospective, long-term 
follow-up study about continuous subcutaneous apomor-
phine infusion in PD patients with cognitive dysfunction.49 
The study demonstrated that apomorphine infusion is an 
effective treatment in advanced PD patients with cognitive 
dysfunction, including visual hallucinations and orthostatic 
hypotension.49 Combined use of DBS and an apomorphine 
pump can be considered in patients with adverse effects on 
axial functions, such as altered gait or dysarthria47,50. 
Continuous enteral infusion of levodopa/carbidopa 
gel (LCIG) was tested in small studies published in 198651 
and 198852, and then in a long-term study developed at the 
University of Uppsala, Sweden53, as a therapeutic alternative 
for the advanced stage of the disease. It is a combination of 
levodopa (20 mg/mL) and carbidopa (5 mg/mL) in a pseu-
doplastic gel and is delivered directly into the proximal jeju-
num by means of a portable infusion pump and duodenal 
catheter11,53. It has the advantage that it ensures a stable flow 
of dopamine into the striatum and, consequently, an increase 
in “on” time without dyskinesias11,53. It also improves nonmo-
tor symptoms such as drowsiness, fatigue, impaired attention, 
memory loss, and gastrointestinal, urinary and cardiovascu-
lar problems53. Ricciardi et al.54 evaluated 24-hour infusion of 
LCIG in eight PD patients to address severe nocturnal dyski-
nesia unresponsive to oral therapies. They found significant 
improvements in fatigue and sleep quality, mood/cognition, 
hallucinations, and urinary function, and there was no change 
in motor severity or motor complications. The most common 
adverse effect is dyskinesia, although this is less common 
than with oral treatment2,28,53,55. Long-term use of high doses of 
levodopa leads to increased homocysteine levels and reduced 
cobalamin metabolism. The risk of severe infections such as 
peritonitis is low. Nevertheless, such infections, if they occur, 
Table 2. Comparison of the different treatment options.
Variable Indication Advantages of the procedure Disadvantages of the procedure Adverse effects
Deep brain 
stimulation
The best option in cases of 
dyskinesia 
Less need for dopamine medication
Invasive therapy with 
surgical risks such 






Can lead to worsening of 
speech, postural instability 
and freezing of gait
Non-ablative  
Better for refractory tremor  
Apomorphine
Rescue from “off” 
episodes Mildly invasive
Frequent blood tests 
and ECG are required
Local, systemic, 
hematological and 
psychiatric (see Table 1)
Motor fluctuations
Parenteral administration (important 
for patients who cannot tolerate oral 
medication or have poor absorption) 
Requires relatives or 
caregivers to handle 
the pump
 
Crosses the blood-brain barrier 
quickly without any need for active 
transport and without competing 




Frequent “off” periods or 
severe dyskinesia 
More physiological release of 









Less invasive than DBS 




Can improve postural 
problems and produce 
some response in gait
Safe.  
  No age limit; mild and moderate dementia are not contraindications  
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can lead to death53,55.  Other adverse effects may include skin 
problems at the surgical site, weight loss and peripheral axonal 
neuropathy, the mechanism of which is poorly understood53. 
There are small trials comparing apomorphine infusion and 
LCIG, showing that the apomorphine pump is easier for care-
givers and patients to use, and is less expensive56-58. However, if 
apomorphine infusion does not yield satisfactory results, jeju-
nal levodopa may be indicated11,12,58. 
The choice of apomorphine or LCIG depends on the 
individual patient and should take into account the adverse 
effects and technical aspects of each therapy11,12,58,59. The 
expert consensus groups recognize the rapid and consistent 
relief from the symptoms of PD provided by apomorphine. 
Its mode of delivery is less invasive than DBS or LCIG, other 
therapies also considered for the treatment of this stage of 
the disease. Also, apomorphine infusion can be easily and 
immediately reversed, either when adverse effects occur or 
at the patient’s request60. Table 2 summarizes the main thera-
pies discussed here.
CONCLUSION
Apomorphine is a treatment option for advanced 
Parkinson’s disease that is well tolerated and optimizes 
motor fluctuations and nonmotor symptoms frequently 
found in the condition. It is another treatment option that 
can be used to improve the patient’s quality of life. 
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